Andere Sprachen Marvel Biosciences Corp.

Aktien

A3EQVV

CA57384M1077

MRVL

Markt geschlossen - Toronto S.E. Andere Börsenplätze 21:54:44 18.04.2024			% 5 Tage	% 1. Jan.
0,14 ^CAD	0,00 %		0,00 %	+75,00 %

26.03.	Marvel Biosciences Corp. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 31. Januar 2024	CI
25.03.	Marvel Biosciences gibt positive Zwischenergebnisse für MB-204 bekannt	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	26.03.
Marvel Biosciences Announces Positive Interim Results For MB-204	25.03.
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Positive Interim Results on Tau Phosphorylation with MB-204	25.03.
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204	25.03.
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB204	12.03.
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204	12.03.
Marvel Biosciences Announces Testing MB-204 on Autism by French University	20.02.
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Testing MB-204 on Autism by French University	20.02.
Marvel Biosciences Announces Testing MB-204 on Autism by French University	20.02.
Marvel Biosciences Announces Closing of Non-Brokered Private Placement	19.01.
Marvel Biosciences Corp. announced that it has received CAD 0.5 million in funding	19.01.
Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel	08.01.
Marvel Biosciences Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	18.12.
Marvel Biosciences Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	28.11.
Marvel Biosciences Invited to Test MB-204 on Autism by French University	16.11.
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials	22.08.23
Marvel Biosciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23.06.23
Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to enter Human Trials	21.04.23
Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	30.03.23
Marvel Biosciences Corp. and its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Initiate 4-Week Good Laboratory Practice FDA Investigational New Drug Enabling Dose-Ranging Rat Studies for its Lead Drug Candidate MB-204	09.03.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Marvel Biosciences Corp.

Aktien

A3EQVV

CA57384M1077

MRVL

Andere Sprachen

Filter